This Phase 2 clinical trial, sponsored by the Masonic Cancer Center at the University of Minnesota, evaluates FDA-approved CAR-T therapies (Kymriah, Yescarta, and Tecartus) for treating hematologic malignancies, specifically B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The trial's focus on multiple CAR-T products positions it strategically within a competitive landscape dominated by established therapies. The outcomes may influence market dynamics, particularly in the pediatric and adult oncology segments, where CAR-T therapies are gaining traction. The trial's results could enhance the commercial viability of these therapies, especially in refractory cases, and provide critical data for regulatory submissions and market access strategies.